Vertex Commits To Novel Reimbursement Plan For Orkambi In UK, Despite Setback

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

Despite an initial rejection from NHS England, Vertex remains committed to bringing its novel reimbursement plan to England to secure access to its cystic fibrosis drug, Orkambi.

Arrow
Vertex remains committed to its portfolio approach. • Source: Shutterstock

Vertex still aims to convince NHS England and NICE, the health technology appraisal institute for England and Wales, that its proposed portfolio approach is the best way to get its cystic fibrosis drug, Orkambi (lumacaftor/ivacaftor) to patients and “get ahead” of certain problems in the reimbursement process. Despite the NHS England turning down the proposal last week, Vertex believes that it could repeat the success of this approach in the UK that it has seen in Ireland.

The deal that the company put forward to NHS England in February this year is similar to the approach used...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

EU Pharma Reform: What You Need to Know Now

 
• By Anabel Costa-Ferreira and Ian Schofield

As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Nancy Test Circulable Section Geography

 
• By Brian Bossetta

This is a short description